Hechingen, Germany

Ulrich Schraermeyer

USPTO Granted Patents = 2 

 

 

Average Co-Inventor Count = 1.7

ph-index = 1


Company Filing History:


Years Active: 2016-2019

Loading Chart...
Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Ulrich Schraermeyer: Innovator in Medical Treatments

Introduction

Ulrich Schraermeyer is a notable inventor based in Hechingen, Germany. He has made significant contributions to the field of medical treatments, particularly in addressing lipofuscin-related diseases and age-related macular degeneration (AMD). With a total of 2 patents, Schraermeyer has developed innovative methods and compounds that hold promise for improving patient outcomes.

Latest Patents

Schraermeyer's latest patents include groundbreaking methods for the determination of compounds or compositions for the treatment of lipofuscin-related diseases. One of his notable inventions is a method for selecting a compound or composition suitable for treating lipofuscin-associated diseases in a patient. This method involves determining a reactivity factor and a targeting factor that allows for cellular uptake and targeting of lipofuscin. Additionally, he has developed a medication comprising tetrahydropyridoethers for use in the treatment of AMD.

Career Highlights

Throughout his career, Ulrich Schraermeyer has worked with prominent companies such as Katairo GmbH and Takeda GmbH. His work in these organizations has allowed him to collaborate with leading experts in the field and contribute to the advancement of medical treatments.

Collaborations

Some of Schraermeyer's notable coworkers include Michael W. Burnet and Jörg Senn-Bilfinger. Their collaborative efforts have further enhanced the development of innovative solutions in the medical field.

Conclusion

Ulrich Schraermeyer is a distinguished inventor whose work has the potential to transform treatments for lipofuscin-related diseases and AMD. His innovative patents and collaborations reflect his commitment to advancing medical science and improving patient care.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…